Refine
Has Fulltext
- yes (22)
Is part of the Bibliography
- yes (22)
Year of publication
Document Type
- Journal article (20)
- Preprint (2)
Language
- English (22)
Keywords
- COVID-19 (2)
- Herpesvirus (2)
- RNA polymerase II (2)
- SARS-CoV-2 (2)
- autoimmunity (2)
- binding protein (2)
- fusion and fission (2)
- gene expression (2)
- herpes simplex virus (2)
- identification (2)
- latency (2)
- miR-30 (2)
- miRNA processing (2)
- mitochondria (2)
- transcription (2)
- type I interferon (2)
- viral load (2)
- virology (2)
- virus reactivation (2)
- AIDS (1)
- Antisense (1)
- BBC3 (1)
- C-terminal domain (1)
- COVID‐19 vaccination (1)
- DNA transcription (1)
- HHV-6 (1)
- HHV-6A (1)
- HIV (1)
- HIV infections (1)
- Herpes (1)
- ICP27 (1)
- ICP4 (1)
- IncRNA (1)
- NFKB (1)
- NK cells (1)
- RQQ domain (1)
- RT-qPCR (1)
- SARS‐CoV‐2 infection (1)
- Salmo trutta fario (1)
- T cell receptor (1)
- T cells (1)
- Transcription (1)
- Virology (1)
- Virus (1)
- allogeneic stem cell transplantation (1)
- alpha-globin (1)
- animal models (1)
- antiviral treatment (1)
- anti‐SARS‐CoV‐2‐spike IgG (1)
- aorta ring (1)
- biochemical assays (1)
- bioinformatic (1)
- black trout syndrome (1)
- brown trout (1)
- cellular stress responses (1)
- characterization and analytical techniques (1)
- cholesteryl ester (1)
- chromatin (1)
- complex (1)
- cryptic peptides (1)
- decay (1)
- defective ribosomal products (1)
- degradation (1)
- diacylglycerol (1)
- dogs (1)
- domain (1)
- drug adherence (1)
- endothelial cell infection (1)
- expression (1)
- genetics (1)
- hACE2 (1)
- healthcare workers (1)
- herpes virus (1)
- highly-active antiretroviral therapy (1)
- histones (1)
- host shutoff (1)
- human cytomegalovirus (HCMV) (1)
- immune activation (1)
- immunology (1)
- infected-cell protein (1)
- interferon signaling (1)
- large gene lists (1)
- lyso-phospholipids (1)
- magnetic properties and materials (1)
- messenger RNA (1)
- microRNA (1)
- microbiology (1)
- molecular biology (1)
- motif discovery (1)
- motifs (1)
- multihit targeting (1)
- murine cytomegalovirus (MCMV) (1)
- nanoparticles (1)
- neutral sphingomyelinase-2 (1)
- next generation sequencing (1)
- non-canonical translation (1)
- orthoreovirus (1)
- parasitology (1)
- piscine orthoreovirus (1)
- plasma membrane (1)
- poly(A) site usage (1)
- polyadenylation (1)
- pre-messenger RNA (1)
- proliferative darkening syndrome (1)
- promoter-proximal pausing (1)
- regulatory protein ICP27 (1)
- remdesivir (1)
- sequence (1)
- seroprevalence (1)
- splicing (1)
- splicing inhibition (1)
- sterol pathway (1)
- stress (1)
- thermal stresses (1)
- transcriptional termination (1)
- translation (1)
- type 1 (1)
- type 1 ICP27 (1)
- viral infection (1)
- viral replication (1)
- virus (1)
- virus host interaction (1)
- viruses (1)
Institute
- Institut für Virologie und Immunbiologie (22)
- Theodor-Boveri-Institut für Biowissenschaften (4)
- Lehrstuhl für Biochemie (2)
- Medizinische Klinik und Poliklinik II (2)
- Frauenklinik und Poliklinik (1)
- Institut für Anatomie und Zellbiologie (1)
- Institut für Hygiene und Mikrobiologie (1)
- Institut für Mathematik (1)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
EU-Project number / Contract (GA) number
- 721016 (4)
- 101041177 (1)
- 677673 (1)
- 955974 (1)
- CoG 721016–HERPES (1)
- ERC-2016-CoG 721016-HERPES (1)
Introduction
Human cytomegalovirus (HCMV) causes significant morbidity and mortality in allogeneic stem cell transplant (alloSCT) recipients. Recently, antiviral letermovir prophylaxis during the first 100 days after alloSCT replaced PCR-guided preemptive therapy as the primary standard of care for HCMV reactivations. Here, we compared NK-cell and T-cell reconstitution in alloSCT recipients receiving preemptive therapy or letermovir prophylaxis in order to identify potential biomarkers predicting prolonged and symptomatic HCMV reactivation.
Methods
To that end, the NK-cell and T-cell repertoire of alloSCT recipients managed with preemptive therapy (n=32) or letermovir prophylaxis (n=24) was characterized by flow cytometry on days +30, +60, +90 and +120 after alloSCT. Additionally, background-corrected HCMV-specific T-helper (CD4+IFNγ+) and cytotoxic (CD8+IFNγ+CD107a+) T cells were quantified after pp65 stimulation.
Results
Compared to preemptive therapy, letermovir prophylaxis prevented HCMV reactivation and decreased HCMV peak viral loads until days +120 and +365. Letermovir prophylaxis resulted in decreased T-cell numbers but increased NK-cell numbers. Interestingly, despite the inhibition of HCMV, we found high numbers of “memory-like” (CD56dimFcεRIγ- and/or CD159c+) NK cells and an expansion of HCMV-specific CD4+ and CD8+ T cells in letermovir recipients. We further compared immunological readouts in patients on letermovir prophylaxis with non/short-term HCMV reactivation (NSTR) and prolonged/symptomatic HCMV reactivation (long-term HCMV reactivation, LTR). Median HCMV-specific CD4+ T-cell frequencies were significantly higher in NSTR patients (day +60, 0.35 % vs. 0.00 % CD4+IFNγ+/CD4+ cells, p=0.018) than in patients with LTR, whereas patients with LTR had significantly higher median regulatory T-cell (Treg) frequencies (day +90, 2.2 % vs. 6.2 % CD4+CD25+CD127dim/CD4+ cells, p=0.019). ROC analysis confirmed low HCMV specific CD4+ (AUC on day +60: 0.813, p=0.019) and high Treg frequencies (AUC on day +90: 0.847, p=0.021) as significant predictors of prolonged and symptomatic HCMV reactivation.
Discussion
Taken together, letermovir prophylaxis delays HCMV reactivation and alters NK- and T-cell reconstitution. High numbers of HCMV-specific CD4+ T cells and low numbers of Tregs seem to be pivotal to suppress post-alloSCT HCMV reactivation during letermovir prophylaxis. Administration of more advanced immunoassays that include Treg signature cytokines might contribute to the identification of patients at high-risk for long-term and symptomatic HCMV reactivation who might benefit from prolonged administration of letermovir.
Herpesviruses have mastered host cell modulation and immune evasion to augment productive infection, life-long latency and reactivation thereof 1,2. A long appreciated, yet elusively defined relationship exists between the lytic-latent switch and viral non-coding RNAs 3,4. Here, we identify miRNA-mediated inhibition of miRNA processing as a thus far unknown cellular mechanism that human herpesvirus 6A (HHV-6A) exploits to disrupt mitochondrial architecture, evade intrinsic host defense and drive the lytic-latent switch. We demonstrate that virus-encoded miR-aU14 selectively inhibits the processing of multiple miR-30 family members by direct interaction with the respective pri-miRNA hairpin loops. Subsequent loss of miR-30 and activation of the miR-30/p53/Drp1 axis triggers a profound disruption of mitochondrial architecture. This impairs induction of type I interferons and is necessary for both productive infection and virus reactivation. Ectopic expression of miR-aU14 triggered virus reactivation from latency, identifying viral miR-aU14 as a readily drugable master regulator of the herpesvirus lytic-latent switch. Our results show that miRNA-mediated inhibition of miRNA processing represents a generalized cellular mechanism that can be exploited to selectively target individual members of miRNA families. We anticipate that targeting miR-aU14 provides exciting therapeutic options for preventing herpesvirus reactivations in HHV-6-associated disorders.